Parkinson's Disease Market is Expected to Showcase a Significant Growth at a CAGR of 5.8% During the Study Period (2020–2034) | DelveInsight
12 déc. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Parkinson's Disease Market is Expected to Showcase a Significant Growth at a CAGR of 5.8% During the Study Period (2020–2034) | DelveInsight The...
Annovis to Host Year-End Investor Webcast on December 11, 2024
25 nov. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased...
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
22 oct. 2024 07h57 HE
|
ZyVersa Therapeutics
Newly published data show that obesity leads to progressive brain inflammation that worsens with prolonged obesity and increased age.
Adaptive Research Launches Decentralized Clinical Trial in Parkinson’s Disease
15 oct. 2024 08h30 HE
|
Adaptive Research Inc
Adaptive Research announced its participation in a decentralized study for Parkinsons’ Disease sponsored by PhotoPharmics Inc.
Allyx Therapeutics Awarded $3.3 Million NIH Grant to Support Further Clinical Studies of Lead Candidate ALX-001
15 oct. 2024 07h05 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics has been awarded a $3.3 million grant as part of the NIH's Small Business Innovation Research Commercial Readiness Pilot program
Norton Healthcare acquires groundbreaking focused ultrasound technology
14 oct. 2024 13h26 HE
|
Norton Healthcare
LOUISVILLE, Ky., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Norton Neuroscience Institute is the first and only facility in Kentucky to offer MRI-guided high-frequency focused ultrasound for essential...
Vanqua Bio Announces Positive Interim Results from Phase 1 Clinical Trial of VQ-101, an Orally Administered, Brain-Penetrant, Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders
09 oct. 2024 07h30 HE
|
Vanqua Bio
VQ-101 is the first small molecule to demonstrate > 75% activation of the lysosomal enzyme glucocerebrosidase (GCase) in humansIn healthy volunteers, VQ-101 was well tolerated and achieved...
Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001
04 sept. 2024 08h00 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics first patient first patient has been dosed with its lead compound, ALX-001, in new Parkinson's Disease clinical study
SPARK NS Awards Five Projects Up to $10 Million to Advance Academic Discoveries in Parkinson’s Disease from the Lab to the Clinic
20 août 2024 09h46 HE
|
SPARK NS
MENLO PARK, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SPARK NS today announced the five projects and principal investigators selected for the 2024 SPARK NS Parkinson’s Disease Translational Research...
Cell and Gene Therapy in Parkinson's Disease Market to Register Stunning Growth During the Study Period (2020–2034) | DelveInsight
22 juil. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, July 22, 2024 (GLOBE NEWSWIRE) -- Cell and Gene Therapy in Parkinson's Disease Market to Register Stunning Growth During the Study Period (2020–2034) | DelveInsight The cell and...